CIBC Private Wealth Group
SRPT icon

CIBC Private Wealth Group’s Sarepta Therapeutics SRPT Stock Holding History

CIBC Private Wealth Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.56K Sell
119
-156
-57% -$3.29K ﹤0.01% 2763
2025
Q3 		$5.3K Buy
275
+24
+10% +$428 ﹤0.01% 2546
2025
Q2 		$4.29K Sell
251
-267
-52% -$11.4K ﹤0.01% 2483
2025
Q1 		$25.5K Buy
518
+5
+1% +$526 ﹤0.01% 1909
2024
Q4 		$64.8K Sell
513
-187
-27% -$22.9K ﹤0.01% 1584
2024
Q3 		$87.4K Buy
700
+236
+51% +$32.6K ﹤0.01% 1546
2024
Q2 		$70.3K Sell
464
-8
-2% -$1.03K ﹤0.01% 1533
2024
Q1 		$60.6K Buy
+472
New +$57.8K ﹤0.01% 1595
2022
Q4 		– Sell
-8,525
Closed -$942K – 932
2022
Q3 		$942K Buy
8,525
+8,519
+141,983% +$859K ﹤0.01% 599
2022
Q2 		$0 Buy
+6
New +$441 ﹤0.01% 1292
2021
Q2 		– Sell
-2,732
Closed -$204K – 1066
2021
Q1 		$204K Sell
2,732
-1,456
-35% -$134K ﹤0.01% 990
2020
Q4 		$714K Sell
4,188
-1,352
-24% -$200K ﹤0.01% 699
2020
Q3 		$778K Buy
+5,540
New +$842K ﹤0.01% 603
2020
Q2 		– Sell
-6,549
Closed -$641K – 787
2020
Q1 		$641K Sell
6,549
-939
-13% -$107K ﹤0.01% 577
2019
Q4 		$966K Sell
7,488
-123
-2% -$12.4K ﹤0.01% 585
2019
Q3 		$573K Sell
7,611
-567
-7% -$67K ﹤0.01% 668
2019
Q2 		$1.24M Sell
8,178
-919
-10% -$112K ﹤0.01% 533
2019
Q1 		$1.08M Buy
9,097
+387
+4% +$49.8K ﹤0.01% 573
2018
Q4 		$951K Sell
8,710
-585
-6% -$73.2K ﹤0.01% 574
2018
Q3 		$1.5M Buy
9,295
+145
+2% +$19.8K 0.01% 586
2018
Q2 		$1.21M Sell
9,150
-130
-1% -$12.3K ﹤0.01% 612
2018
Q1 		$688K Sell
9,280
-600
-6% -$40K ﹤0.01% 716
2017
Q4 		$550K Buy
9,880
+190
+2% +$10.1K ﹤0.01% 761
2017
Q3 		$440K Buy
+9,690
New +$387K ﹤0.01% 791

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

CIBC Private Wealth Group's SRPT Position: Q4 2025 in Review

CIBC Private Wealth Group reduced its Sarepta Therapeutics (SRPT) stake by 57% in Q4 2025, selling an estimated $3.29K and leaving 119 shares worth $2.56K. The position accounts for ﹤0.01% of the portfolio, ranked #2763.

CIBC Private Wealth Group first reported a position in SRPT in Q3 2017 and has held it in 24 quarters since. The position peaked at $1.5M in Q3 2018. 347 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

  • CIBC Private Wealth Group held 119 shares of Sarepta Therapeutics worth $2.56K as of Q4 2025.
  • CIBC Private Wealth Group sold 156 Sarepta Therapeutics shares in Q4 2025, an estimated $3.29K.
  • Sarepta Therapeutics made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #2763 holding.
  • CIBC Private Wealth Group first reported a position in Sarepta Therapeutics in Q3 2017 and has held it in 24 quarters since.
  • CIBC Private Wealth Group's Sarepta Therapeutics position peaked at $1.5M in Q3 2018.
  • 347 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.